Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Veracyte (VCYT) over the last 12 years, with Q3 2025 value amounting to $10.8 million.

  • Veracyte's Share-based Compensation rose 2297.93% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.3 million, marking a year-over-year increase of 2401.56%. This contributed to the annual value of $36.2 million for FY2024, which is 937.81% up from last year.
  • Latest data reveals that Veracyte reported Share-based Compensation of $10.8 million as of Q3 2025, which was up 2297.93% from $11.0 million recorded in Q2 2025.
  • In the past 5 years, Veracyte's Share-based Compensation ranged from a high of $11.0 million in Q2 2025 and a low of $3.9 million during Q1 2021
  • Over the past 5 years, Veracyte's median Share-based Compensation value was $7.9 million (recorded in 2021), while the average stood at $8.0 million.
  • In the last 5 years, Veracyte's Share-based Compensation soared by 15471.03% in 2021 and then tumbled by 743.52% in 2022.
  • Over the past 5 years, Veracyte's Share-based Compensation (Quarter) stood at $6.7 million in 2021, then grew by 2.01% to $6.9 million in 2022, then grew by 9.39% to $7.5 million in 2023, then grew by 28.18% to $9.6 million in 2024, then grew by 11.71% to $10.8 million in 2025.
  • Its last three reported values are $10.8 million in Q3 2025, $11.0 million for Q2 2025, and $11.0 million during Q1 2025.